Irinotecan and temozolomide in recurrent Ewing sarcoma: an analysis in 51 adult and pediatric patients.
Emanuela PalmeriniR L JonesE SetolaP PicciE MarchesiR LukschG GrignaniM CesariA LonghiM E AbateA PaioliZ SzucsLorenzo D'AmbrosioK ScotlandiF FagioliS AsafteiS FerrariPublished in: Acta oncologica (Stockholm, Sweden) (2018)
This series confirms the activity of TEMIRI in both adults and pediatric patients. This schedule offers a 71% DCR, independently of the line of chemotherapy. Predictive factors of response are ECOG and LDH.